Demonstrated strong safety and favorable pharmacokinetics in Phase 1 study A First-in-class oral small molecule modulating immune cell metabolism via glycogen phosphorylase inhibition Once-daily oral ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results